Home » Healthcare » Pharmaceuticals » Hereditary Angioedema Market

Hereditary Angioedema Market By Drug Class (C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others); By Route of Administration (Oral, Parenteral); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Hereditary Angioedema Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-07-11
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Hereditary Angioedema Market

Summary
Table Of Content
Request Sample

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Hereditary Angioedema Market Size 2024	USD 3,144.8 million
Hereditary Angioedema Market, CAGR	6.33%
Hereditary Angioedema Market Size 2032	USD 5,161.2 million

Market Overview

The Hereditary Angioedema market size was valued at USD 2,010.4 million in 2018, increased to USD 3,144.8 million in 2024, and is anticipated to reach USD 5,161.2 million by 2032, at a CAGR of 6.33% during the forecast period.

The Hereditary Angioedema market is driven by leading players such as Takeda Pharma, CSL Behring, Pharming Group, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals, Shire plc, Teva Pharmaceutical Industries Ltd., iBio, Inc., and Attune Pharmaceuticals. These companies focus on expanding their treatment portfolios through strategic R&D and regulatory approvals, particularly in the development of targeted and oral therapies. North America leads the global market with a 31.2% share in 2024, supported by advanced healthcare infrastructure, high awareness, and strong reimbursement frameworks. Europe and Asia Pacific follow, driven by rising diagnosis rates and increased access to biologics. The competitive landscape remains concentrated, with key players leveraging partnerships and innovations to strengthen their global presence and address the growing demand for effective long-term HAE treatments.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Insights

The Hereditary Angioedema market was valued at USD 3,144.8 million in 2024 and is projected to reach USD 5,161.2 million by 2032, growing at a CAGR of 6.33% during the forecast period.
Market growth is primarily driven by increased awareness, early diagnosis, and the rising adoption of targeted therapies like C1-esterase inhibitors and kallikrein inhibitors for both acute and prophylactic treatments.
A notable trend is the shift toward oral therapies, especially oral kallikrein inhibitors, offering greater patient convenience and driving demand across outpatient and home care settings.
The market is moderately consolidated with key players such as Takeda Pharma, CSL Behring, and Pharming Group leading innovation; emerging companies are contributing through clinical advancements in oral and long-acting therapies.
Regionally, North America held a 31.2% market share in 2024, followed by Asia Pacific (26%) and Europe (21.9%); by drug class, C1-esterase inhibitors accounted for the largest segment share.

Market Segmentation Analysis:

By Drug Class:

The Hereditary Angioedema market is segmented into C1-esterase inhibitors, Bradykinin B2 receptor antagonists, Kallikrein inhibitors, and others. Among these, C1-esterase inhibitors dominate the market, accounting for the largest revenue share in 2024. Their efficacy in both acute and prophylactic treatment of HAE attacks has contributed significantly to their widespread adoption. Additionally, advancements in plasma-derived and recombinant formulations have improved safety profiles, enhancing patient compliance. The rising preference for targeted therapies and the strong clinical track record of C1-inhibitors continue to drive growth within this segment.

For instance, BioCryst Pharmaceuticals’ ORLADEYO (berotralstat), the first once-daily oral kallikrein inhibitor, has been prescribed to more than 2,000 HAE patients globally since its U.S. launch in December 2020.

By Route of Administration

Based on the route of administration, the Hereditary Angioedema market is classified into oral and parenteral segments. Parenteral administration held the dominant share in 2024 due to its rapid onset of action and higher bioavailability, especially in acute attack management. Intravenous and subcutaneous formulations of C1-esterase inhibitors and kallikrein inhibitors are widely used in clinical settings. However, the oral segment is expected to witness steady growth owing to increasing patient preference for convenient dosing and the approval of oral kallikrein inhibitors, offering ease of administration without compromising efficacy.

For instance, CSL Behring’s Berinert (C1-INH) is administered intravenously and has shown to reduce the median time to onset of symptom relief to 15 minutes, as per clinical trial NCT00288769.

By Distribution Channel

The market is segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies led the market in 2024, supported by the requirement for immediate access to injectable treatments and the critical nature of managing acute HAE episodes. Their ability to store and dispense specialized medications in a controlled environment contributes to their dominant position. Nevertheless, the online pharmacy segment is expanding rapidly, driven by growing digitalization, ease of access to specialty drugs, and favorable reimbursement models, especially for chronic and prophylactic therapy users.

Market Overview

Advancements in Targeted Therapies

The growing adoption of targeted therapies such as C1-esterase inhibitors, kallikrein inhibitors, and bradykinin B2 receptor antagonists has significantly driven the Hereditary Angioedema (HAE) market. These drugs offer more precise and effective treatment options with fewer side effects compared to traditional therapies. The availability of both acute and prophylactic treatment regimens has enhanced patient outcomes and increased demand. Continuous clinical research and regulatory approvals for novel agents are expected to expand therapeutic options and further strengthen market growth in the coming years.

For instance, Pharvaris’s oral bradykinin B2 receptor antagonist, PHVS416, showed a mean time to symptom relief of 1.6 hours in Phase 2 RAPIDe-1 trial (NCT04618211), compared to 9.1 hours in the placebo group.

Rising Awareness and Diagnosis Rates

Increased awareness campaigns by healthcare organizations and patient advocacy groups have led to improved diagnosis rates for HAE. Historically underdiagnosed due to its rarity and overlapping symptoms with other conditions, HAE is now receiving greater clinical attention. Enhanced genetic screening and improved physician education have enabled early and accurate diagnosis, allowing timely initiation of treatment. This shift is contributing to a larger treated patient pool, thereby accelerating market expansion across both developed and emerging economies.

For instance, HAEi Global Access Program facilitated access to diagnostics and treatment in over 100 countries, helping to identify and treat over 2,500 previously undiagnosed HAE patients since its launch.

Favorable Reimbursement and Regulatory Landscape

The HAE market benefits from supportive reimbursement policies and an encouraging regulatory environment in major regions such as North America and Europe. Many governments and private insurers cover high-cost therapies due to the severity and chronic nature of the disease. Additionally, orphan drug designations and fast-track approvals by regulatory authorities have incentivized pharmaceutical companies to invest in the development of HAE treatments. These factors collectively lower the financial burden on patients and improve access to life-saving medications.

Key Trends & Opportunities

Shift Toward Oral Prophylactic Therapies

A notable trend in the HAE market is the shift from injectable treatments to oral prophylactic therapies. The launch of oral kallikrein inhibitors has transformed long-term disease management by offering improved convenience, compliance, and quality of life. This shift addresses patient concerns related to injection-site reactions and the burden of frequent infusions. The growing preference for oral therapies presents an opportunity for manufacturers to invest in more patient-centric treatment modalities and expand their market share.

For instance, BioCryst Pharmaceuticals’ Orladeyo (berotralstat), the first once-daily oral kallikrein inhibitor approved for HAE, demonstrated a mean reduction of 2.3 HAE attacks per month in patients treated over a 24-week period in the APeX-2 study (NCT03485911).

Emergence of Personalized and Genetic Medicine

The rise of personalized medicine and genetic profiling presents a significant opportunity in HAE management. As HAE is a hereditary condition, advances in genetic testing and biomarker discovery are enabling early diagnosis and tailored therapies. Pharmaceutical companies are increasingly focusing on precision-based drug development to target specific mutations and patient subtypes. This approach improves treatment efficacy and minimizes adverse effects, paving the way for innovation in both diagnostics and therapeutics within the HAE market.

For instance, Ionis Pharmaceuticals’ IONIS-PKK-LRx (donidalorsen) reduced mean plasma prekallikrein concentration from 5.3 µg/mL to 0.16 µg/mL and decreased the mean number of monthly HAE attacks from 3.6 to 0.2 over a 16-week treatment period in its Phase 2 trial (NCT04030598).

Key Challenges

High Cost of Treatment

One of the primary challenges in the HAE market is the high cost of available therapies. Biologics and specialty drugs for HAE can cost thousands of dollars annually per patient, placing a financial burden on healthcare systems and uninsured individuals. Despite reimbursement support in some regions, cost-related barriers still limit access in low- and middle-income countries. This price sensitivity remains a major hurdle for market penetration and equitable treatment access globally.

Limited Patient Pool Due to Rarity

Hereditary Angioedema is an ultra-rare disorder, affecting a small population globally, which poses a challenge for market scalability. The limited patient pool restricts clinical trial sizes, slows down drug development timelines, and reduces commercial viability for some pharmaceutical players. This scarcity also leads to difficulties in physician awareness and delayed diagnosis in less developed regions. As a result, manufacturers must balance high R&D costs with relatively low market volumes.

Complexity in Disease Management and Misdiagnosis

HAE symptoms often mimic those of more common conditions, leading to frequent misdiagnosis and inappropriate treatment. The complexity of disease management, including distinguishing between HAE subtypes and identifying triggering factors, makes it challenging for general practitioners to initiate proper care. Delays in diagnosis and suboptimal treatment regimens can compromise patient outcomes and hinder the overall effectiveness of healthcare delivery, posing a challenge to market growth and treatment standardization.

Regional Analysis

North America

North America dominated the Hereditary Angioedema market in 2024, holding a significant market share of approximately 31.2%, with a valuation of USD 981.35 million, up from USD 645.52 million in 2018. The region is projected to reach USD 1,548.36 million by 2032, registering a CAGR of 5.8% during the forecast period. This strong growth is attributed to high disease awareness, advanced diagnostic infrastructure, and the presence of key pharmaceutical players. Supportive reimbursement policies and early adoption of novel therapies further reinforce the region’s leadership in the global market for Hereditary Angioedema treatment.

Europe

Europe accounted for around 21.9% of the global Hereditary Angioedema market share in 2024, with a market size of USD 687.90 million, increasing from USD 437.85 million in 2018. The market is anticipated to reach USD 1,135.46 million by 2032, expanding at a CAGR of 6.4%. The region’s growth is driven by increased diagnosis rates, favorable healthcare reimbursement systems, and growing clinical research activities. Additionally, rising patient access to biologics and improved healthcare policies in countries like Germany, France, and the UK contribute to consistent market expansion across the continent.

Asia Pacific

Asia Pacific represented approximately 26.0% of the global Hereditary Angioedema market in 2024, with a value of USD 816.74 million, rising from USD 498.17 million in 2018. The market is expected to reach USD 1,422.43 million by 2032, growing at the fastest regional CAGR of 7.1%. This growth is fueled by increasing awareness, expanding healthcare infrastructure, and improving access to genetic testing and treatment in countries such as China, India, and Japan. Additionally, rising healthcare spending and favorable government initiatives support the region’s upward market trajectory in rare disease management.

Latin America

Latin America held a market share of about 11.2% in 2024, with revenues increasing to USD 351.77 million, up from USD 226.16 million in 2018. The market is forecast to reach USD 572.89 million by 2032, progressing at a CAGR of 6.2%. Growing awareness of hereditary angioedema and gradual improvements in diagnostic and treatment capabilities are contributing to regional growth. Brazil and Mexico are key markets, supported by government-backed rare disease programs and increasing penetration of specialty pharmaceuticals. However, access limitations and economic disparities pose challenges to widespread adoption of novel therapies.

Middle East

The Middle East captured a modest 5.4% share of the global Hereditary Angioedema market in 2024, valued at USD 171.30 million, up from USD 108.56 million in 2018. The market is anticipated to reach USD 284.38 million by 2032, growing at a CAGR of 6.5%. The growth is supported by rising investments in healthcare infrastructure, increasing awareness of rare genetic disorders, and expanding availability of advanced biologics. The Gulf Cooperation Council (GCC) countries, particularly the UAE and Saudi Arabia, are spearheading regional development through government-led health initiatives and partnerships with global biotech companies.

Africa

Africa accounted for the smallest share of the Hereditary Angioedema market at 4.3% in 2024, with a market size of USD 135.72 million, rising from USD 94.08 million in 2018. The market is projected to reach USD 197.67 million by 2032, recording a CAGR of 4.7%, the lowest among all regions. Limited healthcare access, low diagnosis rates, and high costs of biologic therapies remain key constraints. However, gradual improvements in healthcare access, increased funding for rare disease programs, and international support from NGOs and health agencies are expected to foster incremental growth over the forecast period.

Market Segmentations:

By Drug Class

C1-esterase inhibitor
Bradykinin B2 receptor antagonist
Kallikrein inhibitor
Others

By Route of Administration

Oral
Parenteral

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Geography:

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Competitive Landscape

The Hereditary Angioedema (HAE) market is characterized by a concentrated competitive landscape, with a few key players driving innovation and market share. Companies such as Takeda Pharma, CSL Behring, Pharming Group, and Ionis Pharmaceuticals dominate the space with established product portfolios and strong global distribution networks. These players focus heavily on research and development to introduce novel therapies, particularly oral and subcutaneous options, aimed at improving patient convenience and compliance. Strategic collaborations, licensing agreements, and acquisitions further strengthen their market positions and expand treatment accessibility. Emerging biopharmaceutical firms like KalVista Pharmaceuticals and Attune Pharmaceuticals are contributing to pipeline diversification, particularly in the development of next-generation kallikrein inhibitors. The market also benefits from orphan drug incentives and favorable regulatory frameworks, enabling faster product approvals. Overall, the competitive environment is marked by a blend of established pharmaceutical giants and agile innovators, all striving to address unmet clinical needs and improve quality of life for HAE patients.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Takeda Pharma
CSL Behring
Pharming Group
Ionis Pharmaceuticals Inc.
KalVista Pharmaceuticals
Shire plc
Teva Pharmaceutical Industries, Ltd.
iBio, Inc
Attune Pharmaceuticals

Recent Developments

In June 2025, the U.S. FDA approved CSL Behring’s Andembry, a monoclonal antibody designed to prevent hereditary angioedema (HAE) attacks in patients aged 12 years and older. Andembry is the first prophylactic therapy to specifically target factor XIIa, offering a novel approach to HAE prevention. It is self-administered once a month via a prefilled pen, enhancing patient convenience and adherence. This U.S. approval follows earlier regulatory clearances in Japan, Europe, and the U.K.
In February 2025, Takeda (TSE:4502/NYSE:TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with hereditary angioedema.
In May 2024, Ionis announced positive Phase 3 results for donidalorsen (OASIS-HAE and OASISplus studies), showing significant and sustained reduction in HAE attack rates, with over 90% improvement after one year for both monthly and every two-month dosing.

Market Concentration & Characteristics

The Hereditary Angioedema Market shows moderate concentration, with a small group of established pharmaceutical companies controlling a significant portion of global revenue. Key players include Takeda Pharma, CSL Behring, and Pharming Group, each holding a strong product pipeline and global distribution networks. It features high entry barriers due to the complexity of biologic drug development, stringent regulatory pathways, and limited patient population. Companies focus on specialized treatment options targeting disease mechanisms such as C1-inhibitor deficiency and kallikrein activity. The market reflects characteristics typical of rare disease segments, including high per-patient treatment costs and strong reliance on orphan drug designations. Innovation plays a central role, with a shift toward oral therapies and long-term prophylactic solutions. Demand remains steady due to the chronic and potentially life-threatening nature of the condition, which drives the need for continuous treatment and follow-up care. Reimbursement structures in developed regions support patient access, while low awareness and limited healthcare resources restrict growth in several low- and middle-income countries. The market benefits from focused R&D efforts and strategic collaborations, contributing to product diversification and expanded reach.

Report Coverage

The research report offers an in-depth analysis based on Drug Class, Route of Administration, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The market will continue to expand due to increasing awareness and early diagnosis of hereditary angioedema.
Oral prophylactic therapies will gain traction, improving patient adherence and convenience.
Key players will invest in developing next-generation therapies with fewer side effects and longer duration.
Genetic testing will play a greater role in accurate and early disease identification.
Regulatory support for orphan drugs will encourage further innovation and faster approvals.
North America and Europe will maintain strong market positions due to robust healthcare infrastructure.
Asia Pacific will show significant growth driven by rising healthcare access and disease recognition.
Online pharmacies will emerge as a preferred channel for distribution, especially for chronic therapies.
Collaboration between biotech firms and large pharmaceutical companies will increase.
Research will focus on expanding treatment options for all subtypes of hereditary angioedema.

CHAPTER NO. 1 : GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 : EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 : HEREDITARY ANGIOEDEMA MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

CHAPTER NO. 4 : KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Drug Class Categories

4.3 Distribution Channel Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Drug Class, Route of Administration, and Distribution Channel Revenue

CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS

6.1. Import Analysis By Region

6.1.1. Global Hereditary Angioedema Market Import Revenue By Region

6.2. Export Analysis By Region

6.2.1. Global Hereditary Angioedema Market Export Revenue By Region

CHAPTER NO. 7 : COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Hereditary Angioedema Market: Company Market Share

7.2. Global Hereditary Angioedema Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Drug Class Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8 : HEREDITARY ANGIOEDEMA MARKET – BY DRUG CLASS SEGMENT ANALYSIS

8.1. Hereditary Angioedema Market Overview By Drug Class Segment

8.1.1. Hereditary Angioedema Market Revenue Share By Drug Class

8.2. C1-esterase inhibitor

8.3. Bradykinin B2 receptor antagonist

8.4. Kallikrein inhibitor

8.5. Others

CHAPTER NO. 9 : HEREDITARY ANGIOEDEMA MARKET – BY ROUTE OF ADMINISTRATION SEGMENT ANALYSIS

9.1. Hereditary Angioedema Market Overview By Route of Administration Segment

9.1.1. Hereditary Angioedema Market Revenue Share By Route of Administration

9.2. Oral

9.3. Parenteral

CHAPTER NO. 10 : HEREDITARY ANGIOEDEMA MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS

10.1. Hereditary Angioedema Market Overview By Distribution Channel Segment

10.1.1. Hereditary Angioedema Market Revenue Share By Distribution Channel

10.2. Hospital Pharmacies

10.3. Retail Pharmacies

10.4. Online Pharmacies

CHAPTER NO. 11 : HEREDITARY ANGIOEDEMA MARKET – REGIONAL ANALYSIS

11.1. Hereditary Angioedema Market Overview By Region Segment

11.1.1. Global Hereditary Angioedema Market Revenue Share By Region

10.1.2. Regions

11.1.3. Global Hereditary Angioedema Market Revenue By Region

11.1.4. Drug Class

11.1.5. Global Hereditary Angioedema Market Revenue By Drug Class

11.1.6. Route of Administration

11.1.7. Global Hereditary Angioedema Market Revenue By Route of Administration

11.1.8. Distribution Channel

11.1.9. Global Hereditary Angioedema Market Revenue By Distribution Channel

CHAPTER NO. 12 : NORTH AMERICA HEREDITARY ANGIOEDEMA MARKET – COUNTRY ANALYSIS

12.1. North America Hereditary Angioedema Market Overview By Country Segment

12.1.1. North America Hereditary Angioedema Market Revenue Share By Region

12.2. North America

12.2.1. North America Hereditary Angioedema Market Revenue By Country

12.2.2. Drug Class

12.2.3. North America Hereditary Angioedema Market Revenue By Drug Class

12.2.4. Route of Administration

12.2.5. North America Hereditary Angioedema Market Revenue By Route of Administration

12.2.6. Distribution Channel

12.2.7. North America Hereditary Angioedema Market Revenue By Distribution Channel

12.3. U.S.

12.4. Canada

12.5. Mexico

CHAPTER NO. 13 : EUROPE HEREDITARY ANGIOEDEMA MARKET – COUNTRY ANALYSIS

13.1. Europe Hereditary Angioedema Market Overview By Country Segment

13.1.1. Europe Hereditary Angioedema Market Revenue Share By Region

13.2. Europe

13.2.1. Europe Hereditary Angioedema Market Revenue By Country

13.2.2. Drug Class

13.2.3. Europe Hereditary Angioedema Market Revenue By Drug Class

13.2.4. Route of Administration

13.2.5. Europe Hereditary Angioedema Market Revenue By Route of Administration

13.2.6. Distribution Channel

13.2.7. Europe Hereditary Angioedema Market Revenue By Distribution Channel

13.3. UK

13.4. France

13.5. Germany

13.6. Italy

13.7. Spain

13.8. Russia

13.9. Rest of Europe

CHAPTER NO. 14 : ASIA PACIFIC HEREDITARY ANGIOEDEMA MARKET – COUNTRY ANALYSIS

14.1. Asia Pacific Hereditary Angioedema Market Overview By Country Segment

14.1.1. Asia Pacific Hereditary Angioedema Market Revenue Share By Region

14.2. Asia Pacific

14.2.1. Asia Pacific Hereditary Angioedema Market Revenue By Country

14.2.2. Drug Class

14.2.3. Asia Pacific Hereditary Angioedema Market Revenue By Drug Class

14.2.4. Route of Administration

14.2.5. Asia Pacific Hereditary Angioedema Market Revenue By Route of Administration

14.2.6. Distribution Channel

14.2.7. Asia Pacific Hereditary Angioedema Market Revenue By Distribution Channel

14.3. China

14.4. Japan

14.5. South Korea

14.6. India

14.7. Australia

14.8. Southeast Asia

14.9. Rest of Asia Pacific

CHAPTER NO. 15 : LATIN AMERICA HEREDITARY ANGIOEDEMA MARKET – COUNTRY ANALYSIS

15.1. Latin America Hereditary Angioedema Market Overview By Country Segment

15.1.1. Latin America Hereditary Angioedema Market Revenue Share By Region

15.2. Latin America

15.2.1. Latin America Hereditary Angioedema Market Revenue By Country

15.2.2. Drug Class

15.2.3. Latin America Hereditary Angioedema Market Revenue By Drug Class

15.2.4. Route of Administration

15.2.5. Latin America Hereditary Angioedema Market Revenue By Route of Administration

15.2.6. Distribution Channel

15.2.7. Latin America Hereditary Angioedema Market Revenue By Distribution Channel

15.3. Brazil

15.4. Argentina

15.5. Rest of Latin America

CHAPTER NO. 16 : MIDDLE EAST HEREDITARY ANGIOEDEMA MARKET – COUNTRY ANALYSIS

16.1. Middle East Hereditary Angioedema Market Overview By Country Segment

16.1.1. Middle East Hereditary Angioedema Market Revenue Share By Region

16.2. Middle East

16.2.1. Middle East Hereditary Angioedema Market Revenue By Country

16.2.2. Drug Class

16.2.3. Middle East Hereditary Angioedema Market Revenue By Drug Class

16.2.4. Route of Administration

16.2.5. Middle East Hereditary Angioedema Market Revenue By Route of Administration

16.2.6. Distribution Channel

16.2.7. Middle East Hereditary Angioedema Market Revenue By Distribution Channel

16.3. GCC Countries

16.4. Israel

16.5. Turkey

16.6. Rest of Middle East

CHAPTER NO. 17 : AFRICA HEREDITARY ANGIOEDEMA MARKET – COUNTRY ANALYSIS

17.1. Africa Hereditary Angioedema Market Overview By Country Segment

17.1.1. Africa Hereditary Angioedema Market Revenue Share By Region

17.2. Africa

17.2.1. Africa Hereditary Angioedema Market Revenue By Country

17.2.2. Drug Class

17.2.3. Africa Hereditary Angioedema Market Revenue By Drug Class

17.2.4. Route of Administration

17.2.5. Africa Hereditary Angioedema Market Revenue By Route of Administration

17.2.6. Distribution Channel

17.2.7. Africa Hereditary Angioedema Market Revenue By Distribution Channel

17.3. South Africa

17.4. Egypt

17.5. Rest of Africa

CHAPTER NO. 18 : COMPANY PROFILES

18.1. Takeda Pharma

18.1.1. Company Overview

18.1.2. Product Portfolio

18.1.3. Financial Overview

18.1.4. Recent Developments

18.1.5. Growth Strategy

18.1.6. SWOT Analysis

18.2. CSL Behring

18.3. Pharming Group

18.4. Ionis Pharmaceuticals Inc.

18.5. KalVista Pharmaceuticals

18.6. Shire plc

18.7. Teva Pharmaceutical Industries, Ltd.:

18.8. iBio, Inc

18.9. Attune Pharmaceuticals

18.10. Other Key Players

Request Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently Asked Questions

What is the current size of the Hereditary Angioedema Market?

The Hereditary Angioedema Market was valued at USD 3,144.8 million in 2024.

What factors are driving the growth of the Hereditary Angioedema Market?

Key drivers include rising disease awareness, early diagnosis, and increased adoption of targeted therapies.

What are some challenges faced by the Hereditary Angioedema Market?

Challenges include high treatment costs, limited patient pool, and frequent misdiagnosis.

Who are the major players in the Hereditary Angioedema Market?

Leading players include Takeda Pharma, CSL Behring, Pharming Group, and Ionis Pharmaceuticals.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports By Keyword

Hereditary Testing Market

The global hereditary testing market is anticipated to grow at a substantial CAGR of 6.10% in the upcoming years. The global hereditary testing market was estimated to be worth USD 5,729.5 Million in 2021 and was expected to be worth USD 8,173.51 Million by 2028.

Transthyretin Amyloidosis Treatment Market

The transthyretin amyloidosis treatment market is projected to grow from USD 6,620 million in 2024 to USD 19,070.4 million by 2032, registering a strong CAGR of 14.14% during the forecast period.

Gene Panel Market

The Gene Panel Market is projected to grow from USD 1,395.48 million in 2024 to USD 3,775.98 million by 2032, at a compound annual growth rate (CAGR) of 13.25%.

Spastic Paraplegia 50 Market

The global spastic paraplegia 50 (SPG50) market is projected to expand from USD 135.5 million in 2024 to USD 292.57 million by 2032, reflecting a compound annual growth rate (CAGR) of 10.10%

Angioedema Treatment Market

Between 2024 and 2032, the global angioedema treatment market is expected to develop at a compound annual growth rate (CAGR) of 17.20%, from its estimated USD 4315.2 million in 2023 to USD 18003.18 million in 2032.

Purchase Options

Single User

$4999

Multi User

$6999

Enterprise

$12999

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Report delivery within 24 to 48 hours

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample